Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Kalvista Pharmaceuticals Inc

KALV
Current price
12.00 USD +0.27 USD (+2.30%)
Last closed 11.50 USD
ISIN US4834971032
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 596 587 200 USD
Yield for 12 month +4.90 %
1Y
3Y
5Y
10Y
15Y
KALV
21.11.2021 - 28.11.2021

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts. Address: 55 Cambridge Parkway, Cambridge, MA, United States, 02142

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

26.33 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-86 167 000 USD

Last Year

-802 000 USD

Current Quarter

Last Quarter

Key Figures KALV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -180 520 992 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -58.15 %
PEG Ratio
Return On Equity TTM -150.50 %
Wall Street Target Price 26.33 USD
Revenue TTM 3 824 000 USD
Book Value 2.93 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 30.70 %
Dividend Yield
Gross Profit TTM -81 066 000 USD
Earnings per share -3.77 USD
Diluted Eps TTM -3.77 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics KALV

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History KALV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 1:14
Payout Ratio
Last Split Date 22.11.2016

Stock Valuation KALV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 76.33
Price Sales TTM 107.42
Enterprise Value EBITDA -3.53
Price Book MRQ 4.11

Financials KALV

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators KALV

For 52 weeks

7.30 USD 15.50 USD
50 Day MA 11.21 USD
Shares Short Prior Month 5 836 841
200 Day MA 11.07 USD
Short Ratio 9.43
Shares Short 5 855 046
Short Percent 13.30 %